QUIZ: The ALEX Study for ALK+ Non-Small Cell Lung Cancer
In our lung cancer quiz, you’ll get to test your knowledge on the ALEX study.
What characteristics of alectinib therapy made it a viable treatment option versus crizotinib.
a. It has greater potency/selectivity for ALK.
b. It is a central nervous system penetrant.
c. It has the ability to target resistance mutations.
d. All of the above
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Related Content
